# Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response ("INB")

### Informal, intersessional briefing on <u>Access to technology: promoting sustainable and equitably</u> <u>distributed production and transfer of technology and know-how</u> in the context of strengthening pandemic prevention, preparedness and response

#### **Concept Note**

At its fourth meeting, the INB decided that the INB Bureau would organize informal intersessional work between INB4 and INB5, with the participation of relevant stakeholders, on related matters, as appropriate, of the <u>WHO CA+ zero draft</u>.

### **Key Information**

Date and time	20 March 2023 14:30 – 17:30 (CEST)
Location, participation, and webcasting	The session will be hybrid, with interpretation in WHO's official languages. The WHO Secretariat has provided the connection details to all participants in advance of the session.
Chairs	Ms Precious Matsoso and Mr Roland Driece, INB Bureau Co-Chairs
Topic #1 Article 7. Access to technology: promoting sustainable and equitably distributed production and <u>transfer of</u> <u>technology and</u> <u>know-how</u>	<ul> <li>Panelists</li> <li>Antony Taubman, WTO</li> <li><i>TBC</i>, WIPO</li> <li>Erika Duenas, WHO</li> <li>Questions to consider</li> <li>What went wrong during COVID-19 in relation to this topic?</li> <li>What can be improved for the future?</li> <li>What are the provisions and/or mechanisms to ensure timely and equitable access, which could be adapted for pandemic-related products?</li> <li>What are your comments on specific provisions of the Zero draft and how best these can be operationalized with the TRIPS safeguards in mind?</li> </ul>
Topic #2	Panelists
Article 7. Access to technology: promoting <u>sustainable and</u> <u>equitably</u> <u>distributed</u> <u>production</u> and transfer of technology and know-how	<ul> <li>Charles Gore, Medicines Patent Pool</li> <li>Bruce Aylward, ACT-A</li> <li>Frank van Rompaey (<i>TBC</i>), UNIDO</li> <li>Martin Friede, WHO mRNA Vaccine Technology Transfer Hub</li> <li>Questions to consider</li> <li>What is the progress made so far on the transfer hub?</li> <li>What went wrong during COVID-19 in relation to this topic?</li> <li>What can be improved for the future?</li> <li>Are the provisions/measures in the zero draft sufficient? If not, why and what else is needed?</li> </ul>

# **Modalities**

The informal intersessional briefing will be conducted in two parts: 1) a brief introduction/presentation (no slides) from each panelist; and 2) a discussion and reflection session, for Member States and relevant stakeholders, where questions and reflections may be presented during the session.

## **Run of Show**

14:10 - 14:25	Panelists join the session and test their connection
14:30 - 14:40	Welcome remarks by the INB Co-chairs
Topic #1	Article 7. Access to technology: promoting sustainable and equitably distributed production and <u>transfer of technology and know-how</u>
14:40 - 15:00	Panelists' remarks (5 min/speaker)
15:00 - 16:00	Discussion and reflection session, involving audience and panelists
Topic #2	Article 7. Access to technology: <u>promoting sustainable and equitably</u> <u>distributed production</u> and transfer of technology and know-how
16:00 - 16:20	Panelists' remarks (5 min/speaker)
16:20 - 17:20	Discussion and reflection session, involving audience and panelists
17:20 - 17:30	Outline of main messages and closing remarks by the INB Co-chairs

### **Disclaimer / understanding**

Mindful of the informal nature of the intersessional briefings and the goal of stimulating full and frank discussion, the following understandings will apply: it is understood that discussions, including among panelists, in no way prejudice the positions of Member States or any other session participants. It is further understood that any comments or questions presented by session participants, including Member States, do not imply a view or position of Member States or other session participants. It is also understood that presentations are provided solely for the consideration by Member States, and are not themselves sources of input to the zero draft or subsequent drafts.